PhRMA allegedly kills Bill in California

6 April 2008

An attempt in the state of California, USA, to restrict gifts from drugmakers to physicians to less than $250 looks set to fail after a proposed law (AB 2821) failed to clear the review stage in the Assembly's Health Committee. According to the California Progress Report, which favors elements of the Democratic party, the failure to carry the legislation to the next stage was the fault of Democrat members of the Committee, seven of whom failed to attend or abstained. The entire Republican party's representation on the review panel rejected the proposals, meaning that nine Democrats were needed. In the event, only five did so.

The California Progress Report claimed that the Pharmaceutical Research and Manufacturers of America (PhRMA) "smothered" AB 2821. The same source claimed this is 10% of current practice for many drug companies. In addition to the ban on more expensive gifts, all items valued at $50 or more would be required by law to be disclosed by physicians.

The California Medical Association did not take sides on the legislation, arguing in favor of transparency but questioning some of the studies which claim that physicians are manipulated by drugmakers' gifts into altering their prescribing habits. Such conclusions question the integrity of the entire medical profession, the CMA believes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight